Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.

Rossing P, Block GA, Chin MP, Goldsberry A, Heerspink HJL, McCullough PA, Meyer CJ, Packham D, Pergola PE, Spinowitz B, Sprague SM, Warnock DG, Chertow GM.

Kidney Int. 2019 May 16. pii: S0085-2538(19)30503-4. doi: 10.1016/j.kint.2019.04.027. [Epub ahead of print]

PMID:
31377056
2.

Prevention of brain damage after traumatic brain injury by pharmacological enhancement of KCNQ (Kv7, "M-type") K+ currents in neurons.

Vigil FA, Bozdemir E, Bugay V, Chun SH, Hobbs M, Sanchez I, Hastings SD, Veraza RJ, Holstein DM, Sprague SM, M Carver C, Cavazos JE, Brenner R, Lechleiter JD, Shapiro MS.

J Cereb Blood Flow Metab. 2019 Jul 4:271678X19857818. doi: 10.1177/0271678X19857818. [Epub ahead of print]

PMID:
31272312
3.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
4.

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.

Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW.

Am J Nephrol. 2019;49(4):284-293. doi: 10.1159/000499187. Epub 2019 Mar 15.

PMID:
30878999
5.

Cortical Perfusion and Tubular Function as Evaluated by Magnetic Resonance Imaging Correlates with Annual Loss in Renal Function in Moderate Chronic Kidney Disease.

Prasad PV, Li LP, Thacker JM, Li W, Hack B, Kohn O, Sprague SM.

Am J Nephrol. 2019;49(2):114-124. doi: 10.1159/000496161. Epub 2019 Jan 22.

PMID:
30669143
6.

Multicenter Study Evaluating Intrarenal Oxygenation and Fibrosis Using Magnetic Resonance Imaging in Individuals With Advanced CKD.

Prasad PV, Li W, Raj DS, Carr J, Carr M, Thacker J, Li LP, Wang C, Sprague SM, Ix JH, Chonchol M, Block G, Cheung AK, Raphael K, Gassman J, Wolf M, Fried LF, Isakova T; CKD Optimal Management with BInders and NicotinamidE (COMBINE) study group.

Kidney Int Rep. 2018 Jul 7;3(6):1467-1472. doi: 10.1016/j.ekir.2018.07.006. eCollection 2018 Nov. No abstract available.

7.

Mineral and Bone Disease in Kidney Transplant Recipients.

Altman AM, Sprague SM.

Curr Osteoporos Rep. 2018 Dec;16(6):703-711. doi: 10.1007/s11914-018-0490-4. Review.

PMID:
30390201
8.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Chertow GM, Appel GB, Block GA, Chin MP, Coyne DW, Goldsberry A, Kalantar-Zadeh K, Meyer CJ, Molitch ME, Pergola PE, Raskin P, Silva AL, Spinowitz B, Sprague SM, Rossing P.

J Diabetes Complications. 2018 Dec;32(12):1113-1117. doi: 10.1016/j.jdiacomp.2018.09.005. Epub 2018 Sep 13.

9.

Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease.

Sprague SM, Strugnell SA, Bishop CW.

Expert Rev Endocrinol Metab. 2017 Sep;12(5):289-301. doi: 10.1080/17446651.2017.1347501. Epub 2017 Jul 11.

PMID:
30058895
10.

Sucroferric oxyhydroxide for the treatment of hyperphosphatemia.

Sprague SM, Floege J.

Expert Opin Pharmacother. 2018 Jul;19(10):1137-1148. doi: 10.1080/14656566.2018.1491548. Epub 2018 Jul 9. Review.

PMID:
29985725
11.

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.

Ketteler M, Sprague SM, Covic AC, Rastogi A, Spinowitz B, Rakov V, Walpen S, Floege J.

Nephrol Dial Transplant. 2019 Jul 1;34(7):1163-1170. doi: 10.1093/ndt/gfy127.

12.

Should phosphate management be limited to the KDIGO/ KDOQI guidelines?

Dhillon-Jhattu S, Sprague SM.

Semin Dial. 2018 Jul;31(4):377-381. doi: 10.1111/sdi.12702. Epub 2018 Apr 19. Review.

PMID:
29671909
13.

Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.

Sprague SM, Ketteler M, Covic AC, Floege J, Rakov V, Walpen S, Rastogi A.

Hemodial Int. 2018 Oct;22(4):480-491. doi: 10.1111/hdi.12663. Epub 2018 Apr 15.

PMID:
29656600
14.

Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging.

Li LP, Tan H, Thacker JM, Li W, Zhou Y, Kohn O, Sprague SM, Prasad PV.

Kidney Int Rep. 2017 Jan;2(1):36-43. doi: 10.1016/j.ekir.2016.09.003. Epub 2016 Sep 13.

15.

Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.

Coyne DW, Ficociello LH, Parameswaran V, Anderson L, Vemula S, Ofsthun NJ, Mullon C, Maddux FW, Kossmann RJ, Sprague SM.

Clin Nephrol. 2017 Aug;88(8):59-67. doi: 10.5414/CN109021.

16.

Imaging in Chronic Kidney Disease-Metabolic Bone Disease.

Alexander AJ, Jahangir D, Lazarus M, Sprague SM.

Semin Dial. 2017 Jul;30(4):361-368. doi: 10.1111/sdi.12598. Epub 2017 Apr 5. Review.

PMID:
28382631
17.

One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.

Floege J, Covic AC, Ketteler M, Mann J, Rastogi A, Spinowitz B, Rakov V, Lisk LJ, Sprague SM.

Nephrol Dial Transplant. 2017 Nov 1;32(11):1918-1926. doi: 10.1093/ndt/gfw460.

PMID:
28339993
18.

Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease.

Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee S, Petkovich PM, Bishop CW.

Am J Nephrol. 2016;44(4):316-325. Epub 2016 Sep 28.

PMID:
27676085
19.

Granzyme A Contributes to Inflammatory Arthritis in Mice Through Stimulation of Osteoclastogenesis.

Santiago L, Menaa C, Arias M, Martin P, Jaime-Sánchez P, Metkar S, Comas L, Erill N, Gonzalez-Rumayor V, Esser E, Galvez EM, Raja S, Simon MM, Sprague SM, Gabay C, Martinez-Lostao L, Pardo J, Froelich CJ.

Arthritis Rheumatol. 2017 Feb;69(2):320-334. doi: 10.1002/art.39857.

20.

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.

Sprague SM, Covic AC, Floege J, Ketteler M, Botha J, Chong EM, Rastogi A.

Am J Nephrol. 2016;44(2):104-12. doi: 10.1159/000447600. Epub 2016 Jul 20.

PMID:
27434393
21.

Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.

Covic AC, Floege J, Ketteler M, Sprague SM, Lisk L, Rakov V, Rastogi A.

Nephrol Dial Transplant. 2017 Aug 1;32(8):1330-1338. doi: 10.1093/ndt/gfw242.

22.

We Do Too Many Parathyroidectomies for Calciphylaxis.

Nigwekar SU, Sprague SM.

Semin Dial. 2016 Jul;29(4):312-4. doi: 10.1111/sdi.12502. Epub 2016 Apr 15.

PMID:
27082830
23.

Multi-Parametric Evaluation of Chronic Kidney Disease by MRI: A Preliminary Cross-Sectional Study.

Prasad PV, Thacker J, Li LP, Haque M, Li W, Koenigs H, Zhou Y, Sprague SM.

PLoS One. 2015 Oct 2;10(10):e0139661. doi: 10.1371/journal.pone.0139661. eCollection 2015.

24.

Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis.

Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, D'Haese PC, Drüeke TB, Du H, Manley T, Rojas E, Moe SM.

Am J Kidney Dis. 2016 Apr;67(4):559-66. doi: 10.1053/j.ajkd.2015.06.023. Epub 2015 Aug 25.

PMID:
26321176
25.

Renal Blood Oxygenation Level-Dependent Magnetic Resonance Imaging: A Sensitive and Objective Analysis.

Thacker JM, Li LP, Li W, Zhou Y, Sprague SM, Prasad PV.

Invest Radiol. 2015 Dec;50(12):821-7. doi: 10.1097/RLI.0000000000000190.

26.

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.

Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA.

J Am Soc Nephrol. 2015 Oct;26(10):2328-39. doi: 10.1681/ASN.2015020117. Epub 2015 May 12. Review.

27.

Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.

Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1021-30. doi: 10.2215/CJN.03270314. Epub 2015 Apr 14.

28.

Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.

Ennis JL, Worcester EM, Coe FL, Sprague SM.

J Nephrol. 2016 Feb;29(1):63-70. doi: 10.1007/s40620-015-0186-0. Epub 2015 Mar 4.

PMID:
25736620
29.

Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.

Floege J, Covic AC, Ketteler M, Mann JF, Rastogi A, Spinowitz B, Chong EM, Gaillard S, Lisk LJ, Sprague SM; Sucroferric Oxyhydroxide Study Group.

Nephrol Dial Transplant. 2015 Jun;30(6):1037-46. doi: 10.1093/ndt/gfv006. Epub 2015 Feb 16.

30.

Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease.

Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M, Messner EJ, White JA, Melnick JZ, Bishop CW.

Am J Nephrol. 2014;40(6):535-45. doi: 10.1159/000369939. Epub 2015 Jan 7.

31.

A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/CJN.10661013. Epub 2014 Jun 26.

32.

A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

Floege J, Covic AC, Ketteler M, Rastogi A, Chong EM, Gaillard S, Lisk LJ, Sprague SM; PA21 Study Group.

Kidney Int. 2014 Sep;86(3):638-47. doi: 10.1038/ki.2014.58. Epub 2014 Mar 19.

33.

A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Zhang Y, Lapidos KA, Gal-Moscovici A, Sprague SM, Ameer GA.

Artif Organs. 2014 Jun;38(6):474-83. doi: 10.1111/aor.12203. Epub 2013 Nov 11.

34.

Painful skin ulcers in a hemodialysis patient.

Sprague SM.

Clin J Am Soc Nephrol. 2014 Jan;9(1):166-73. doi: 10.2215/CJN.00320113. Epub 2013 Nov 7.

35.

Women and CKD-mineral and bone disorder.

Ho LT, Sprague SM.

Adv Chronic Kidney Dis. 2013 Sep;20(5):423-6. doi: 10.1053/j.ackd.2013.06.007. Review.

PMID:
23978548
36.

Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy.

Horstick EJ, Linsley JW, Dowling JJ, Hauser MA, McDonald KK, Ashley-Koch A, Saint-Amant L, Satish A, Cui WW, Zhou W, Sprague SM, Stamm DS, Powell CM, Speer MC, Franzini-Armstrong C, Hirata H, Kuwada JY.

Nat Commun. 2013;4:1952. doi: 10.1038/ncomms2952.

37.

Rebuttal: PTH--a particularly tricky hormone: why measure it at all in kidney patients?

Sprague SM, Moe SM.

Clin J Am Soc Nephrol. 2013 Feb;8(2):321. doi: 10.2215/CJN.10331012. Epub 2012 Nov 15. No abstract available.

38.

CKD-mineral and bone disorder management in kidney transplant recipients.

Alshayeb HM, Josephson MA, Sprague SM.

Am J Kidney Dis. 2013 Feb;61(2):310-25. doi: 10.1053/j.ajkd.2012.07.022. Epub 2012 Oct 26.

PMID:
23102732
39.

The case for routine parathyroid hormone monitoring.

Sprague SM, Moe SM.

Clin J Am Soc Nephrol. 2013 Feb;8(2):313-8. doi: 10.2215/CJN.04650512. Epub 2012 Oct 4.

40.

Impact of serum source and inflammatory cytokines on the isolation of endothelial colony-forming cells from peripheral blood.

Lapidos KA, Sprague SM, Ameer GA.

J Tissue Eng Regen Med. 2014 Sep;8(9):747-56. doi: 10.1002/term.1580. Epub 2012 Aug 8.

PMID:
22888041
41.

Connexin 39.9 protein is necessary for coordinated activation of slow-twitch muscle and normal behavior in zebrafish.

Hirata H, Wen H, Kawakami Y, Naganawa Y, Ogino K, Yamada K, Saint-Amant L, Low SE, Cui WW, Zhou W, Sprague SM, Asakawa K, Muto A, Kawakami K, Kuwada JY.

J Biol Chem. 2012 Jan 6;287(2):1080-9. doi: 10.1074/jbc.M111.308205. Epub 2011 Nov 10.

42.

Variation in parathyroid hormone immunoassay results--a critical governance issue in the management of chronic kidney disease.

Sturgeon CM, Sprague SM, Metcalfe W.

Nephrol Dial Transplant. 2011 Nov;26(11):3440-5. doi: 10.1093/ndt/gfr614. Review.

43.

Impact of CKD on coronary artery calcifications.

Sprague SM.

Am J Kidney Dis. 2011 Oct;58(4):503-5. doi: 10.1053/j.ajkd.2011.08.005. No abstract available.

PMID:
21944960
44.

TRPM7 is required within zebrafish sensory neurons for the activation of touch-evoked escape behaviors.

Low SE, Amburgey K, Horstick E, Linsley J, Sprague SM, Cui WW, Zhou W, Hirata H, Saint-Amant L, Hume RI, Kuwada JY.

J Neurosci. 2011 Aug 10;31(32):11633-44. doi: 10.1523/JNEUROSCI.4950-10.2011.

45.

Is bone mineral density measurement of any value in a dialysis patient?

Sprague SM.

Semin Dial. 2011 Jul-Aug;24(4):433-4. doi: 10.1111/j.1525-139X.2011.00942.x. Epub 2011 Jul 31. No abstract available.

PMID:
21801230
46.

Renal bone disease.

Sprague SM.

Curr Opin Endocrinol Diabetes Obes. 2010 Dec;17(6):535-9. doi: 10.1097/MED.0b013e3283400945. Review.

PMID:
21030840
47.

Early tissue response to citric acid-based micro- and nanocomposites.

Chung EJ, Qiu H, Kodali P, Yang S, Sprague SM, Hwong J, Koh J, Ameer GA.

J Biomed Mater Res A. 2011 Jan;96(1):29-37. doi: 10.1002/jbm.a.32953. Epub 2010 Oct 14.

48.

Evaluation of cinacalcet HCl treatment after kidney transplantation.

Copley JB, Germain M, Stern L, Pankewycz O, Katznelson S, Shah T, Wang O, Turner SA, Sprague SM.

Transplant Proc. 2010 Sep;42(7):2503-8. doi: 10.1016/j.transproceed.2010.04.052.

PMID:
20832532
49.

touché Is required for touch-evoked generator potentials within vertebrate sensory neurons.

Low SE, Ryan J, Sprague SM, Hirata H, Cui WW, Zhou W, Hume RI, Kuwada JY, Saint-Amant L.

J Neurosci. 2010 Jul 14;30(28):9359-67. doi: 10.1523/JNEUROSCI.1639-10.2010.

50.

Use of vitamin D in chronic kidney disease patients.

Gal-Moscovici A, Sprague SM.

Kidney Int. 2010 Jul;78(2):146-51. doi: 10.1038/ki.2010.113. Epub 2010 May 26. Review.

Supplemental Content

Loading ...
Support Center